Mesa Labs' Q2 Revenue Up, Net Income Dips on Lower Other Income

TL;DR

**MLAB's revenue growth is decent, but the net income drop and cash burn are red flags; stay cautious on this one.**

AI Summary

Mesa Laboratories, Inc. reported a mixed financial performance for the three and six months ended September 30, 2025. For the three months, revenues increased by 5.02% to $60.737 million from $57.833 million in the prior year, driven by growth in Biopharmaceutical Development and Calibration Solutions. However, net income decreased by 27.79% to $2.476 million from $3.428 million, primarily due to a significant reduction in 'Other (income), net' from $(3.322) million to $(0.137) million. For the six months, revenues grew by 3.69% to $120.280 million from $116.003 million, while net income saw a modest increase of 5.89% to $7.218 million from $6.816 million. Operating income for the three months rose to $4.724 million from $3.508 million, but for the six months, it declined to $7.788 million from $9.088 million. The company's cash and cash equivalents decreased by $6.899 million to $20.422 million as of September 30, 2025, from $27.321 million at March 31, 2025, largely due to $16.310 million in net cash used in financing activities, including a $9.555 million GKE acquisition-related holdback payment.

Why It Matters

Mesa Laboratories' mixed results highlight the challenges of balancing revenue growth with profitability, especially for investors looking for consistent earnings. The significant decrease in 'Other (income), net' suggests a one-time gain or a change in financial strategy that warrants closer scrutiny, impacting the company's overall financial health. For employees, stable revenue growth across most segments, particularly Biopharmaceutical Development and Calibration Solutions, indicates continued business activity, but the dip in net income could signal cost pressures. Customers might see continued innovation, especially with R&D expenses increasing to $5.048 million for the quarter, but the competitive landscape in life sciences tools remains intense, requiring sustained investment to maintain market position.

Risk Assessment

Risk Level: medium — The company's cash and cash equivalents decreased by $6.899 million for the six months ended September 30, 2025, to $20.422 million, and net income for the three months ended September 30, 2025, declined by 27.79% to $2.476 million. This, coupled with a significant increase in the revolving line of credit to $106.000 million from $10.000 million, indicates increased reliance on debt and potential liquidity concerns.

Analyst Insight

Investors should closely monitor Mesa Laboratories' upcoming earnings calls for explanations regarding the decline in 'Other (income), net' and the increased reliance on its revolving line of credit. Consider holding off on new investments until there's clearer guidance on how the company plans to improve net income and cash flow from operations, especially given the $9.555 million GKE acquisition-related holdback payment.

Financial Highlights

revenue

$60.737M

operating Margin

7.78%

total Assets

$430.351M

total Debt

$251.883M

net Income

$2.476M

eps

$0.45

gross Margin

61.46%

cash Position

$20.422M

revenue Growth

+5.02%

Revenue Breakdown

Key Numbers

• $60.737M — Revenues (3 months) (Increased from $57.833M in prior year, a 5.02% increase)
• $2.476M — Net Income (3 months) (Decreased from $3.428M in prior year, a 27.79% decrease)
• $120.280M — Revenues (6 months) (Increased from $116.003M in prior year, a 3.69% increase)
• $7.218M — Net Income (6 months) (Increased from $6.816M in prior year, a 5.89% increase)
• $20.422M — Cash and Cash Equivalents (Decreased from $27.321M at March 31, 2025)
• $106.000M — Revolving Line of Credit (Increased from $10.000M at March 31, 2025)
• $9.555M — GKE Acquisition Holdback (Payment made during the six months ended September 30, 2025)
• $0.45 — Diluted EPS (3 months) (Decreased from $0.63 in prior year)
• $1.30 — Diluted EPS (6 months) (Increased from $1.25 in prior year)
• $16.310M — Net Cash Used in Financing Activities (For the six months ended September 30, 2025)

Key Players & Entities

• MESA LABORATORIES INC /CO/ (company) — Registrant
• Nasdaq Stock Market LLC (company) — Exchange for Common Stock
• Securities and Exchange Commission (regulator) — Regulatory body for filings
• FASB (regulator) — Financial Accounting Standards Board
• GKE (company) — Acquisition target with holdback payment
• $60.737 million (dollar_amount) — Total revenues for three months ended September 30, 2025
• $2.476 million (dollar_amount) — Net income for three months ended September 30, 2025
• $106.000 million (dollar_amount) — Revolving line of credit as of September 30, 2025
• $9.555 million (dollar_amount) — GKE acquisition-related holdback payment
• $20.422 million (dollar_amount) — Cash and cash equivalents at September 30, 2025

FAQ

Risk Factors

• Debt and Liquidity Management [medium — financial]: The company's cash and cash equivalents decreased by $6.899 million to $20.422 million as of September 30, 2025. This was largely driven by $16.310 million in net cash used in financing activities, including a $9.555 million GKE acquisition-related holdback payment. The revolving line of credit increased significantly from $10.000 million to $106.000 million, indicating a reliance on borrowed funds.
• Integration of Acquisitions [medium — operational]: The company made a $9.555 million GKE acquisition-related holdback payment, suggesting ongoing integration efforts and potential contingent liabilities related to past acquisitions. Successful integration is crucial for realizing the value of these transactions.
• Compliance in Regulated Industries [high — regulatory]: Mesa Laboratories operates in the biopharmaceutical and calibration sectors, which are subject to stringent regulatory oversight. Failure to comply with evolving regulations could lead to penalties, product recalls, or reputational damage.
• Competition in Calibration and Biopharma [medium — market]: The company faces competition in both its Calibration Solutions and Biopharmaceutical Development segments. Sustained revenue growth depends on maintaining a competitive edge through innovation and service quality.
• Impact of 'Other (income), net' [low — financial]: Net income for the three months ended September 30, 2025, decreased by 27.79% to $2.476 million, significantly impacted by a reduction in 'Other (income), net' from $(3.322) million to $(0.137) million. Volatility in this line item can affect reported profitability.

Industry Context

Mesa Laboratories operates in the specialized fields of calibration services and biopharmaceutical development support. The calibration market is characterized by a need for accuracy, compliance with standards, and specialized equipment. The biopharmaceutical development sector requires services that support drug discovery, development, and manufacturing, often involving complex regulatory pathways and a demand for high-quality, reliable testing and validation.

Regulatory Implications

As a provider of critical services to the biopharmaceutical industry, Mesa Laboratories is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP) and other quality standards is paramount. Any lapse in compliance could result in significant penalties, reputational damage, and disruption to client operations.

What Investors Should Do

1. Monitor the utilization and cost of the increased revolving line of credit.
2. Analyze the drivers behind the decrease in 'Other (income), net' for the three-month period.
3. Evaluate the integration progress and financial impact of recent acquisitions, such as GKE.
4. Assess the sustainability of revenue growth in the context of competitive pressures.

Key Dates

• 2025-09-30: End of Second Quarter and Six Months — Reporting period for the 10-Q filing, showing financial performance and position.
• 2025-03-31: End of Fiscal Year and First Quarter — Prior period balance sheet comparison point for cash and debt.

Glossary

Other (income), net

This line item typically includes miscellaneous income and expenses not directly related to the company's core operations, such as interest income, foreign currency gains/losses, and gains/losses on asset sales. (A significant swing in this item from $(3.322) million to $(0.137) million negatively impacted net income for the three months ended September 30, 2025.)

GKE acquisition-related holdback

A portion of the purchase price for an acquisition (GKE) that is held back by the buyer to cover potential future claims or adjustments related to the acquisition. (A payment of $9.555 million for this holdback contributed to the net cash used in financing activities.)

Revolving line of credit

A flexible loan that allows a company to borrow, repay, and re-borrow funds up to a certain limit over a specified period. (The company significantly increased its utilization of this facility, from $10.000 million at March 31, 2025, to $106.000 million at September 30, 2025.)

Convertible notes

Debt securities that can be converted into a predetermined amount of the issuer's equity (stock). (The company had $97.297 million in convertible notes classified as current liabilities at March 31, 2025, which were no longer present in current liabilities by September 30, 2025, indicating they were likely paid off or converted.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (Goodwill increased from $181.760 million to $188.488 million, suggesting recent acquisitions or revaluation.)

Year-Over-Year Comparison

Compared to the prior year, Mesa Laboratories reported a 5.02% increase in revenue for the three months ended September 30, 2025, reaching $60.737 million, driven by growth in Biopharmaceutical Development and Calibration Solutions. However, net income saw a significant decline of 27.79% to $2.476 million, largely due to a favorable swing in 'Other (income), net' in the prior year. For the six-month period, revenue grew by 3.69% to $120.280 million, and net income increased by a modest 5.89% to $7.218 million. Operating income for the three months improved, but declined for the six-month period. A notable change is the substantial increase in the revolving line of credit to $106.000 million from $10.000 million, alongside a decrease in cash and cash equivalents, indicating a shift towards greater leverage.

Filing Documents

• mlab20250930_10q.htm (10-Q) — 1550KB
• ex_883989.htm (EX-10.1) — 1171KB
• ex_876274.htm (EX-10.23) — 129KB
• ex_853528.htm (EX-10.51) — 10KB
• ex_853529.htm (EX-31.1) — 13KB
• ex_853530.htm (EX-31.2) — 13KB
• ex_853531.htm (EX-32.1) — 5KB
• ex_853532.htm (EX-32.2) — 4KB
• jplogo.jpg (GRAPHIC) — 3KB
• 0000724004-25-000013.txt ( ) — 8917KB
• mlab-20250930.xsd (EX-101.SCH) — 54KB
• mlab-20250930_cal.xml (EX-101.CAL) — 49KB
• mlab-20250930_def.xml (EX-101.DEF) — 348KB
• mlab-20250930_lab.xml (EX-101.LAB) — 302KB
• mlab-20250930_pre.xml (EX-101.PRE) — 382KB
• mlab20250930_10q_htm.xml (XML) — 1494KB

Financial Information

Part I. Financial Information 1

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Income 2 Condensed Consolidated Statements of Comprehensive Income 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

Other Information

Part II. Other Information 23

Legal Proceedings

Item 1. Legal Proceedings 23

Risk factors

Item 1A. Risk factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 24

Signatures

Signatures 25 Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a) Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a) Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350 Table of Contents

Financial Information

Part I. Financial Information

. Financial Statements

Item 1 . Financial Statements M esa Laboratories, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share amounts) September 30, March 31, 2025 2025 ASSETS Current assets: Cash and cash equivalents $ 20,422 $ 27,321 Accounts receivable, less allowance for credit losses of $ 1,833 and $ 1,186 , respectively 40,092 41,970 Inventories 27,739 25,365 Prepaid expenses and other current assets 9,180 8,029 Total current assets 97,433 102,685 Noncurrent assets: Property, plant and equipment, net of accumulated depreciation of $ 28,777 and $ 26,421 , respectively 31,835 32,333 Deferred tax asset 1,472 1,371 Other assets 17,855 18,324 Customer relationships, net 70,511 72,880 Other intangibles, net 22,757 23,995 Goodwill 188,488 181,760 Total assets $ 430,351 $ 433,348 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,090 $ 5,747 Accrued payroll and benefits 10,036 17,858 Unearned revenues 14,258 14,710 Other accrued expenses 14,223 24,601 Term loan, current portion 4,688 3,750 Convertible notes, net of debt issuance costs - 97,297 Total current liabilities 48,295 163,963 Noncurrent liabilities: Deferred tax liability 21,661 20,181 Other noncurrent liabilities 11,763 12,472 Term loan, noncurrent portion, net of debt issuance costs 64,164 66,902 Revolving line of credit 106,000 10,000 Total liabilities 251,883 273,518 Stockholders' equity: Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,510,741 and 5,455,421 shares, respectively 365,173 358,541 (Accumulated deficit) ( 183,473 ) ( 188,936 ) Accumulated other comprehensive (loss) ( 3,232 ) ( 9,775 ) Total stockholders' equity 178,468 159,830 Total liabilities and stockholders' equity $ 430,351 $ 433,348 See accompanying notes to Condensed C onsolidated Fi nancial Statements. Page 1 Table of Contents Mesa Laboratories, Inc.

View Full Filing

View this 10-Q filing on SEC EDGAR